What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce and provide Amgen Inc.'s unaudited financial results for the third quarter and the first nine months of 2025. It furnishes a press release containing these results and reconciliations of non-GAAP to GAAP financial measures.

What types of expenses does Amgen exclude when calculating its non-GAAP financial measures?

Amgen excludes several categories of expenses from its non-GAAP financial measures to provide a clearer view of ongoing operations. These include acquisition-related expenses (like amortization and impairment of acquired intangibles), costs from restructuring and cost-saving initiatives (such as severance and facility charges), and other items outside the ordinary course of business (like gains/losses on investments and legal proceeding costs).

Why does Amgen provide non-GAAP financial measures?

Amgen provides non-GAAP financial measures to enhance investors' understanding of its financial performance and future prospects. The company believes these measures facilitate comparisons of ongoing business operations across different periods by excluding items that may be volatile or not reflective of core operational trends. They are also used internally for budgeting, planning, and performance evaluation.

What is Free Cash Flow (FCF) and why is it important according to Amgen?

Free Cash Flow (FCF) is calculated by subtracting capital expenditures from operating cash flow, both as determined in accordance with GAAP. Amgen presents FCF as an additional measure of the company's liquidity, indicating the cash generated from operations after accounting for investments in its assets.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) has filed a Form 8-K detailing its third quarter 2025 financial results, announced via a press release on November 4, 2025. The filing primarily furnishes the press release which includes the company's unaudited financial performance for the three and nine months ended September 30, 2025, as well as its financial position as of that date. Investors should note that Amgen is presenting both GAAP and non-GAAP financial measures, with a detailed reconciliation of these figures provided within the press release. The non-GAAP measures, including earnings per share, operating income, operating margin, tax rate, and operating expenses, are intended to offer a more insightful view of the company's ongoing operational performance by excluding certain items. These excluded items notably include acquisition-related expenses, costs associated with restructuring and cost-saving initiatives, and other non-ordinary course items such as investment gains/losses and legal proceeding costs. Amgen also highlights Free Cash Flow (FCF) as a key liquidity metric.

Key Highlights

1Amgen announced its unaudited third quarter and year-to-date 2025 financial results on November 4, 2025.
2The company is providing both GAAP and non-GAAP financial measures to enhance investor understanding.
3Key non-GAAP metrics discussed include adjusted earnings per share, operating income, and operating margin.
4Excluded from non-GAAP measures are significant items like acquisition-related expenses and restructuring costs.
5Free Cash Flow (FCF) is presented as an important measure of the company's liquidity.
6The press release, furnished as an exhibit, contains detailed reconciliations of non-GAAP to GAAP measures.

AMGEN INC 8-K Report, Financial Results (Nov 4, 2025)

Summary

Key Highlights

Frequently Asked Questions